Study Investigating a Standard Regimen in de Novo Kidney Transplant Patients Versus a Calcineurin Inhibitor (CNI)-Free Regimen and a CNI-low Dose Regimen

NCT00514514 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

802

Enrollment

INDUSTRY

Sponsor class

Conditions

Kidney Transplantation

Interventions

DRUG: Everolimus
DRUG: Myfortic
DRUG: Sandimmun Optoral
DRUG: Simulect®

Sponsor

Novartis Pharmaceuticals